Amgen Inc. (NASDAQ:AMGN) Receives Consensus Rating of “Hold” from Brokerages

Amgen Inc. (NASDAQ:AMGN) has been given an average rating of “Hold” by the twenty-one analysts that are presently covering the stock, reports. Two analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $248.71.

AMGN has been the topic of several recent analyst reports. William Blair restated a “hold” rating on shares of Amgen in a report on Friday, September 17th. Robert W. Baird reiterated a “sell” rating on shares of Amgen in a report on Thursday, August 5th. Mizuho started coverage on Amgen in a report on Friday, September 10th. They set a “hold” rating and a $222.00 target price for the company. SVB Leerink started coverage on Amgen in a report on Sunday, September 19th. They set a “hold” rating for the company. Finally, Morgan Stanley decreased their target price on Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a report on Tuesday, October 12th.

A number of hedge funds have recently bought and sold shares of AMGN. Regency Capital Management Inc. DE purchased a new position in Amgen in the 1st quarter worth approximately $27,000. Maverick Capital Ltd. bought a new stake in shares of Amgen in the 1st quarter worth $27,000. Elmwood Wealth Management Inc. purchased a new position in shares of Amgen in the first quarter worth $31,000. Wolverine Asset Management LLC lifted its holdings in shares of Amgen by 1,587.5% during the first quarter. Wolverine Asset Management LLC now owns 135 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 127 shares in the last quarter. Finally, KB Financial Partners LLC purchased a new stake in shares of Amgen during the first quarter valued at $35,000. 74.73% of the stock is owned by institutional investors.

Shares of AMGN traded up $1.05 during trading hours on Tuesday, hitting $208.68. The company had a trading volume of 1,632,888 shares, compared to its average volume of 2,592,708. The firm has a market cap of $118.50 billion, a P/E ratio of 21.23, a P/E/G ratio of 1.55 and a beta of 0.68. The stock’s 50 day moving average price is $217.97 and its 200 day moving average price is $235.38. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 3.45. Amgen has a 52-week low of $200.47 and a 52-week high of $276.69.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Monday, August 2nd. The medical research company reported $4.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.09 by $0.29. The firm had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $6.43 billion. Amgen had a return on equity of 99.85% and a net margin of 22.55%. On average, research analysts expect that Amgen will post 16.41 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 8th. Investors of record on Tuesday, November 16th will be given a dividend of $1.76 per share. This represents a $7.04 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date is Monday, November 15th. Amgen’s dividend payout ratio (DPR) is presently 42.41%.

About Amgen

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

See Also: Why do earnings reports matter?

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.